<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12(11)</volume><submitter>Wang Q</submitter><pubmed_abstract>Immunotherapies have dramatically improved survival outcome for patients with melanoma. &lt;i>MUC16&lt;/i> encodes cancer antigen 125 (CA125), which is frequently mutated in melanoma. In this study, we correlated the &lt;i>MUC16&lt;/i> mutational status with the following: tumor mutation burden (TML), multiple immune-related signals in microenvironment, deregulated pathways, survival outcome, and immunotherapeutic efficacy. We found that patients with &lt;i>MUC16&lt;/i> mutations had significantly higher TML than those without it. Enriched pro-inflammatory CD8 T cells and M1 macrophages, enhanced interferon gamma (IFNγ) and T cell-inflamed signatures, and increased cytolytic activity were associated with &lt;i>MUC16&lt;/i> mutations. Immune-suppressive M2 macrophages were enriched in patients with wild-type &lt;i>MU</pubmed_abstract><journal>Aging</journal><pagination>10827-10843</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7346065</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring &lt;i>MUC16&lt;/i>/CA125 mutations.</pubmed_title><pmcid>PMC7346065</pmcid><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Wang Q</pubmed_authors><pubmed_authors>Chen K</pubmed_authors><pubmed_authors>Yang M</pubmed_authors></additional><is_claimable>false</is_claimable><name>High mutation load, immune-activated microenvironment, favorable outcome, and better immunotherapeutic efficacy in melanoma patients harboring &lt;i>MUC16&lt;/i>/CA125 mutations.</name><description>Immunotherapies have dramatically improved survival outcome for patients with melanoma. &lt;i>MUC16&lt;/i> encodes cancer antigen 125 (CA125), which is frequently mutated in melanoma. In this study, we correlated the &lt;i>MUC16&lt;/i> mutational status with the following: tumor mutation burden (TML), multiple immune-related signals in microenvironment, deregulated pathways, survival outcome, and immunotherapeutic efficacy. We found that patients with &lt;i>MUC16&lt;/i> mutations had significantly higher TML than those without it. Enriched pro-inflammatory CD8 T cells and M1 macrophages, enhanced interferon gamma (IFNγ) and T cell-inflamed signatures, and increased cytolytic activity were associated with &lt;i>MUC16&lt;/i> mutations. Immune-suppressive M2 macrophages were enriched in patients with wild-type &lt;i>MU</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jun</publication><modification>2025-04-22T19:33:43.161Z</modification><creation>2025-04-06T02:49:10.444Z</creation></dates><accession>S-EPMC7346065</accession><cross_references><pubmed>32491995</pubmed><doi>10.18632/aging.103296</doi></cross_references></HashMap>